Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

In the 70 years following the first description of the benefits of surgical castration, despite advances in medical therapy e.g. cabazitaxel, enzalutamide, abiraterone, androgen deprivation therapy (ADT) remains the cornerstone of treatment for advanced prostate cancer. However, with increasing numb...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourke, L, Kirkbride, P, Hooper, R, Rosario, A J, Chico, T J A, Rosario, D J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553523/
https://www.ncbi.nlm.nih.gov/pubmed/23321508
http://dx.doi.org/10.1038/bjc.2012.523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553523/
https://www.ncbi.nlm.nih.gov/pubmed/23321508
http://dx.doi.org/10.1038/bjc.2012.523

Ejemplares similares